Immunocore Holdings

Immunocore Holdings Plc operates as a holding company. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Earnings data Q4 2020

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Immunocore announces strategic priorities including pipeline expansion for 2023 - 2024

Immunocore announces strategic priorities including pipeline expansion for 2023 -2024

Immunocore to present at the 41 st Annual  J . P . Morgan Healthcare Conference

Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference

Reinsurance Group of America

Vinci SA

IMCR, RGA and VCISY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2022.

Best Momentum Stocks to Buy for December 30th

ACRES Commercial Realty Corp.

LPL Financial Hlds

IMCR, RGA, LPLA, ACR and VCISY have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2022.

New Strong Buy Stocks for December 30th

Gilead Sciences

GlaxoSmithKline

Syndax Pharmaceuticals

New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR and SNDX well amid the volatility.

4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023

Clinical trial momentum within the Melanoma diagnostics and treatment paradigm is gaining steam. Immunocore Holdings plc presents with unique exposure for investors to position at the treatment end of the spectrum.

Immunocore: Potential To Unlock Capital With New Melanoma Treatment Paradigm

Intra-Cellular Therapies

United Therapeutics

Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.

3 Drug Stocks Most Wall Street Analysts Are Bullish About

Immunovant Inc

Merck

Vertex Pharmaceuticals

Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.

4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023

Immunocore is awarded the Prix Galien France award for KIMMTRAK

The consensus price target hints at a 27.1% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Immunocore Holdings PLC Sponsored ADR (IMCR) Climb 27% to Reach the Level Wall Street Analysts Expect?

Immunocore p resents ovarian cancer expansion d ata for ImmTAC ® candidate IMC-C103C targeting MAGE-A4

Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4

Immunocore and Gadeta A nnounce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for S olid Tumors

Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors

Immunocore Holdings PLC Sponsored ADR (IMCR) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Immunocore Holdings PLC Sponsored ADR (IMCR) is on the Move, Here's Why the Trend Could be Sustainable

The consensus price target hints at a 27.8% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Immunocore Holdings PLC Sponsored ADR (IMCR)? Wall Street Analysts Think 28%

Immunocore to present at the  5th Annual Evercore ISI HealthCONx Conference

Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference

Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Medpace (MEDP) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Immunocore (IMCR) This Year?

Immunocore presents new biomarker analysis for KIMMTRAK ( tebentafusp -tebn ) in metastatic uveal melanoma at the SITC 2022 Annual Meeting

Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting

If you are looking for stocks that are well positioned to maintain their recent uptrend, Immunocore Holdings PLC Sponsored ADR (IMCR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

What Makes Immunocore Holdings PLC Sponsored ADR (IMCR) a Good Fit for "Trend Investing"

Immunocore to present at the Jefferies London Healthcare Conference

Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update

Immunocore (IMCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Immunocore (IMCR) Might Surprise This Earnings Season

The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to a 29.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 30% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Here's What You Should Know

Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Strength Seen in Immunocore Holdings PLC Sponsored ADR (IMCR): Can Its 10.2% Jump Turn into More Strength?

The consensus price target hints at a 60.4% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Immunocore Holdings PLC Sponsored ADR (IMCR) Could Rally 60%: Here's is How to Trade

Immunocore Holdings plc has one asset already in the market. It has a pipeline of TCR bispecific molecules targeting various indications.

News for Immunocore Holdings Stock (IMCR)